Exclusive Summary

• - Post-patent, multi-region generic market with EU-27 approvals enables rapid replication into new markets
• - Large ICU and procedural sedation demand; respiratory-sparing profile drives uptake in ventilated and day-surgery settings
• - Endorsed by major critical care guidelines (with propofol ahead of benzodiazepines), offering delirium reduction and extubation benefits
• - Strong compliance: EMA GMP, EU-27 registrations, USP API; fit for distribution and technology transfer pathways
• - Significant cost advantage versus originator and premix bags, supporting tenders and shortage-substitution strategies